Nastech is a clinical-stage biopharmaceutical company focusing on the development and commercialization of innovative therapeutic products based on its proprietary molecular biology-based nasal drug delivery technology and its proprietary ribonucleic acid interference
CytRx is developing ribonucleic acid interference
(RNAi) as a tool to identify drug targets as part of an expanded collaborative agreement with UMMS.
Kriegsman, president and CEO of CytRx Corporation, can share his expertise on Ribonucleic Acid Interference
While ribonucleic acid interference
(RNAi) offers a fresh approach to drug discovery, validation, and delivery, current research efforts are geared toward improving target specificity.
Kriegsman can discuss whether Ribonucleic Acid Interference
(RNAi), a process developed by CytRx, is the key to saving lives by "turning off" the genes that causes diabetes.